4
Changes in Ownership
HALOZYME THERAPEUTICS, INC. Filed Acc 0001415889-24-023657
SVP, CHIEF TECHNICAL OFFICER sold 20,000 shares at an average $62.45 ($1,249,096)
- SVP, CHIEF TECHNICAL OFFICER acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2024-09-17 | Option exercise 10b5-1 | +10,000 | $16.65 | $166,500 | 183,756 | D |
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2024-09-17 | Sale 10b5-1 | −10,000 | $62.88 | $628,780 | 173,756 | D |
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2024-09-18 | Option exercise 10b5-1 | +10,000 | $16.65 | $166,500 | 183,756 | D |
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2024-09-18 | Sale 10b5-1 | −7,963 | $61.89 | $492,838 | 175,793 | D |
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2024-09-18 | Sale 10b5-1 | −2,037 | $62.58 | $127,477 | 173,756 | D |
| Derivatives | |||||||
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2024-09-17 | Option exercise · Option to Purchase Common Stock 10b5-1 | −10,000 | 21,861 | D | ||
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2024-09-18 | Option exercise · Option to Purchase Common Stock 10b5-1 | −10,000 | 11,861 | D | ||
| Open-market sales · 20,000 sh · avg $62.45 · $1,249,096 | |||||||
Loading xslF345X05/form4-09182024_100954.xml…